Quantexa and Oviva backer Albion VCTs close £90M fund for UK deeptech scale-ups — TFN

UK buyers typically battle to entry high-growth startups attributable to financial uncertainty and the excessive prices of early-stage investing. Albion Capital’s three VCTs assist by offering tax-efficient methods to put money into breakthrough applied sciences.

They only closed an oversubscribed £90 million top-up supply. The elevate exceeded the preliminary £60 million goal, triggering the £30 million overallotment facility in December 2025 attributable to robust demand.

Funds will give attention to deeptech, healthcare, and B2B software program corporations, constructing on latest portfolio successes corresponding to Quantexa, Oviva, and tem.

Backing founders who’re reshaping whole industries, and giving them the long-term capital to do it

Albion Capital was established in 1996 by Patrick Reeve, who led Shut Ventures at Shut Brothers earlier than a 2009 administration buyout that created the unbiased agency. Reeve, a chartered accountant with company finance expertise at Cazenove & Co and Shut Brothers, aimed to again visionary UK founders in high-potential sectors.​​

Albion’s mission is to again corporations that don’t simply final, however really transfer the needle, delivering prime returns and real-world impression throughout UK software program, healthcare, and deeptech. It invests in a diversified portfolio of about 70 unquoted UK development corporations, specializing in B2B SaaS, digital well being, fintech, and deeptech at inflexion-point funding levels.

Albion’s key strengths embrace a 30-year observe file with greater than 100 exits, together with Reserving.com. They aim a 5% annual NAV dividend and have delivered strong returns: 6.5% common per 12 months over 5 years and 6.9% over ten years (to June 2025, earlier than tax aid).

In contrast to pure enterprise capital funds, VCTs supply 30% revenue tax aid (as much as £200k), tax-free dividends, and capital features tax exemption. Additionally they present diversified and liquid entry via their itemizing on the London Inventory Change.

This makes them totally different from rivals like Octopus Titan VCT, which focuses on bigger, higher-risk development, ProVen VCT, a generalist, and Mobeus Revenue & Progress VCT, which focuses on revenue.

What’s subsequent?

The £90M is heading straight right into a pipeline of UK scale-ups. Over the past three years, Albion’s helped 64% of its portfolio corporations make the leap from development to scale-up. The main focus stays on deeptech, healthcare, and B2B software program, with latest wins like Gravity and TransFICC main the best way.

With £1B in property beneath administration (about £700M in VCTs), Albion’s gearing up for extra fundraising and exits.